Table 2.

Comparison of clinical data between AKI group and non-AKI group.

	Non-AKI group (N = 102)	AKI group (N = 42)	P-value
Gender
Female	52 (51%)	17 (40%)	0.335
Male	50 (49%)	25 (60%)
Age
< 20y	14 (14%)	7 (17%)	0.747
20–50y	77 (75%)	32 (76%)
> 50y	11 (11%)	3 (7%)
Weight
≤ 50 kg	69 (68%)	29 (69%)	1
> 50 kg	33 (32%)	13 (31%)
FK506
No	85 (83%)	23 (55%)	< 0.001**
Yes	17 (17%)	19 (45%)
Donor source
Auto	21 (21%)	0 (0%)	0.003*
Allo	81 (79%)	42 (100%)
Stem cell source
PB	26 (25%)	13 (31%)	0.643
PB + BM	76 (75%)	29 (69%)
HLA
Mismatch	9 (9%)	14 (33%)	< 0.001**
Match	93 (91%)	28 (67%)
Blood type matching
No	28 (27%)	25 (60%)	< 0.001**
Yes	74 (73%)	17 (40%)
aGVHD
No	83 (81%)	21 (50%)	< 0.001**
Yes	19 (19%)	21 (50%)
HC
No	90 (88%)	35 (83%)	0.604
Yes	12 (12%)	7 (17%)
Vancomycin
No	46 (45%)	17 (40%)	0.746
Yes	56 (55%)	25 (60%)
Sepsis
No	94 (92%)	37 (88%)	0.65
Yes	8 (8%)	5 (12%)
Infection
No	33 (32%)	2 (5%)	< 0.001**
Yes	69 (68%)	40 (95%)
Ganciclovir
No	29 (28%)	9 (21%)	0.51
Yes	73 (72%)	33 (79%)
TBI
No	77 (75%)	28 (67%)	0.381
Yes	25 (25%)	14 (33%)
CSA
No	44 (43%)	21 (50%)	0.57
Yes	58 (57%)	21 (50%)
Triazole antifungals
No	24 (24%)	5 (12%)	0.176
Yes	78 (76%)	37 (88%)
Amphotericin B
No	100 (98%)	40 (95%)	0.71
Yes	2 (2%)	2 (5%)
Implantation syndrome
No	99 (97%)	41 (98%)	1
Yes	3 (3%)	1 (2%)
Secondary diabetes
No	100 (98%)	39 (93%)	0.297
Yes	2 (2%)	3 (7%)
Secondary hypertension
No	89 (87%)	38 (90%)	0.795
Yes	13 (13%)	4 (10%)
Cytomegaloviremia
No	78 (76%)	24 (57%)	0.034*
Yes	24 (24%)	18 (43%)
Basal creatinine
44–106 μmol/L	87 (85%)	33 (79%)	0.461
< 44 μmol/L	15 (15%)	9 (21%)

Tacrolimus (FK506), acute graft versus host disease (aGVHD), hemorrhagic cystitis (HC), total body irradiation (TBI), cyclosporin A(CSA).

*P < 0.05, **P < 0.01.